 One thing we haven't talked about in any of the podcasts, really, and I love that you said that word, and I know very little about it. I pride myself on trying to keep a breath with most things, but sarcomas. I don't see them that often. Obviously it's very rare. So did I understand you correctly that sarcoma has some of the same utilities that pancreatic cancer does as far as fortifying itself, being immune deserts? Is that also why it is just such a stubborn cancer to treat? Yes. So sarcomas is an area that I've developed a lot of interest over the last 20 years and have been doing research in, and it's about 15,000 cases a year in the United States, and there's at least 50 different types of sarcoma, so it's not all one cancer. Many of them have very distinct tumor somatic mutations. The newer approach in sarcoma in research is to combine immunotherapy with a targeted therapy. So just like, and one of the things that many researchers, including myself, have seen is that blood supply, abnormal blood supply that's brought into the tumor due to mutations, which is called angiogenesis, really fights the T cell. It kind of helps mass the T cell, so often the tumors that are the most immune resistant often tend to be also very angiogenic. They tend to have a lot of blood supply. And some of that, you know, bilia, so in those cancers that are being resistant to some of them will respond to immunotherapy, especially if they have a lot of mutations, but sarcomas don't tend to be as mutated. You see more like five, six mutations rather than hundreds of mutations as you see in melanoma, so they don't stand out to the T cell as much, they can hide more. So one of the medicines that a great paper came out in AACR's journal, CCR, it was a medicine called Kavacantinib. And Kavacantinib is a wonderful medicine that dries up the blood supply, so blocks VEGF, it also blocks some of the growth mutations that are driving sarcomas. And so we found that when you combine a medication like Kavacantinib with immunotherapy, you can often get better results. And so a lot of this is in its very early stages of research. We do use the traditional chemotherapies in the advanced stage, but we're actually finding that in some cases we can get better results using targeted therapies and also immunotherapies.